Remove 2014 Remove Communication Remove Drug Development
article thumbnail

Norstella, Citeline merge to create $5bn pharma tech firm

pharmaphorum

With the merger now completed, Norstella becomes a $5 billion group with 1,500 employees across the five business brands with the overarching objective of guiding life sciences companies through the drug development process so patients can get access to therapies more quickly. Photo by Edge2Edge Media on Unsplash.

article thumbnail

Overview of FDA Expedited Development and Approval Programs for Serious Conditions

Syner-G

In May of 2014 and February of 2019 , the FDA released final Guidance for Industry outlining the Agency’s policies and procedures regarding expedited development and review programs for new drugs and biologics intended to treat serious or life-threatening conditions. Category: Regulatory Affairs , Drug Development Consulting.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Preparing for a post-pandemic world

pharmaphorum

Public health agencies and pharma pivoted in countless ways, from decentralising clinical trials and accelerating research and development, to enabling remote care and remote working with rapid digitisation. And we transformed so quickly because the key players communicated and collaborated.

article thumbnail

NHC Comments on NIST Draft March-In Framework

Putting Patients First Blog

Nature Communications, 11(6265). The price of progress: funding and financing Alzheimer’s disease drug development. Translational Medicine Communications, 4(18). [link] 2 Aiyegbusi, O., Macpherson, K., Washington, J., Newsome, P., and Calvert, M. link] 3 Cummings, J., and Kumar, P. link] 5 Seyhan, A.

article thumbnail

The “Medical Bypass”: new drugs to strike obesity

Pharmaceutical Technology

Over the past few years, there has been a boom in anti-obesity drug development, with major companies achieving substantial sales in the field. According to GlobalData, as of November 28, there were 316 generic and novel drugs marketed to treat obesity. Anti-obesity therapeutic landscape.

article thumbnail

The “Medical Bypass”: new drugs to strike obesity

Pharmaceutical Technology

Over the past few years, there has been a boom in anti-obesity drug development, with major companies achieving substantial sales in the field. According to GlobalData, as of November 28, there were 316 generic and novel drugs marketed to treat obesity. Anti-obesity therapeutic landscape.

article thumbnail

FDA’s Issues Draft Guidance on Accelerated Approval: A Substantial Evidentiary and Procedural Overhaul to this High-Profile Pathway

FDA Law Blog: Biosimilars

Since that time, it was formalized in FDA regulations (21 CFR 314 Subpart H) in 1992, codified in the Food, Drug, & Cosmetic Act by FDAMA (21 USC 356(c)) in 1997, revised by FDASIA in 2012, and described in guidance, most importantly, in the 2014 Expedited Programs for Serious Conditions Drugs and Biologics (2014 Guidance).